A Proprietary Set of Wildtype Mice Designed to Achieve Maximum Plasma Titers in Hybridoma Campaigns
Conventional immunization approaches utilized in hybridoma-based antibody discovery campaigns typically use one or two common wildtype (WT) mouse strains (e.g. Balb/c or C57Bl/6). LakePharma’s scientists have noted through a course of over 100 campaigns that this approach likely limits the identification of high-quality antibodies to just those target antigens that are efficiently processed and presented by a restricted major histocompatibility complex (MHC) repertoire.
LakePharma’s PentaMice® Platform is a royalty-free set of mice comprising 5 WT strains that cover 9 distinct MHC haplotypes. A total of 10 mice (2 mice of each strain) are included in each set to achieve maximum plasma titers, thus boosting the opportunity to generate high-quality antibodies in vivo.
The Five Wildtype Strains in the PentaMice® Platform
The Concept Behind the PentaMice® Platform
Client Testimonial: Tri-Institutional Therapeutics Discovery Institute and LakePharma: A Partnership in Antibody Discovery to Enable Innovative Therapeutics
PentaMice®: A Unique Approach to Achieve Maximum Plasma Titers for Antibody Discovery webinar recording available NOW
Discovery of Potent, Functional Anti-BTLA, and Anti-TIGIT Monoclonal Antibodies using Hybridoma and Phage Display Platform webinar recording available NOW!
Download our Pentamice® Flyer by clicking .
"LakePharma is nothing short of a true partner with Apollos Diagnostics. We will continue to work with LakePharma as a partner for all of our future antibody development campaigns."
- John Alderete, Ph.D., MBA; Founder and President of Folium Biomed, LLC